CLAIMS

We claim:

- 1. A pharmaceutical composition comprising PAF-AH enzyme and a pharmaceutically acceptable diluent, adjuvant or carrier.
- 2. A method for treating a mammal susceptible to or suffering from a PAF-mediated pathological condition comprising administering the pharmaceutical composition of claim 1 to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.
- 3. A method for treating a mammal susceptible to or suffering from pleurisy comprising administering the pharmaceutical composition of claim 1 to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF of said mammal.
- 4. A method for treating a mammal susceptible to or suffering from asthma comprising administering the pharmaceutical composition of claim 1 to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF of said mammal.
- 5. A method for treating a mammal susceptible to or suffering from rhinitis comprising administering the pharmaceutical composition of claim 1 to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.
- 6. A method for treating a mammal susceptible to or suffering from necrotizing enterocolitis comprising administering the pharmaceutical composition of claim 1 to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.





7. A method for treating a mammal susceptible to or suffering from acute respiratory distress syndrome comprising administering the pharmaceutical composition of claim 1 to said mammal in an amount sufficient to supplement endogenous PAF-AH activity and to inactivate pathological amounts of PAF in said mammal.



